Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 6/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.34 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.34 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23547992 | 0.88 | PRMT6 (0.40) | PRMT6P2RY12ADORA1P2RY1P2RY2 | |
| SCHEMBL25505318 | 0.86 | PRMT6 (0.39) | PRMT6P2RY12ADORA1 | |
| SCHEMBL25504694 | 0.86 | ADORA1 (0.41) | PRMT6ADORA1 | |
| SCHEMBL7206380 | 0.85 | PRMT6 (0.35) | PRMT6P2RY12 | |
| SCHEMBL21620263 | 0.84 | PRMT6 (0.36) | PRMT6P2RY12ADORA1P2RY1P2RY2 | |
| SCHEMBL17231772 | 0.84 | P2RY12 (0.37) | PRMT6P2RY12P2RY1P2RY2P2RY6 | |
| SCHEMBL5482086 | 0.84 | P2RY12 (0.37) | PRMT6P2RY12P2RY1P2RY2P2RY6 | |
| SCHEMBL5180333 | 0.84 | PRMT6 (0.43) | PRMT6P2RY12P2RY1P2RY2P2RY6 | |
| SCHEMBL19146295 | 0.83 | PRMT6 (0.38) | PRMT6P2RY12 | |
| SCHEMBL23547931 | 0.82 | PRMT6 (0.37) | PRMT6P2RY12ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759473-B2 | Nucleotide oligomer, nucleotide polymer, method for determining structure of functional substance and method for manufacturing functional substance | FUJITSU LIMITED (JP) | 2010-07-20 | — | — | US | disclosed |
| US-20080300393-A1 | Nucleotide oligomer, nucleotide polymer, method for determining structure of functional substance and method for manufacturing functional substance | FUJITSU LIMITED (JP) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300393-A1 | Nucleotide oligomer, nucleotide polymer, method for determining structure of functional substance and method for manufacturing functional substance | RNMT, NT5C3B, ADAR | PRMT6 1332/4885P2RY12 137/4885ADORA1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.